Financial reports
10-K
2023 FY
Annual report
9 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
27 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Results of Operations and Financial Condition
1 Apr 24
8-K
NEXGEL Announces $975,000 Registered Direct Offering Led by Insiders
21 Feb 24
8-K
Regulation FD Disclosure
31 Jan 24
8-K
Departure of Directors or Certain Officers
16 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Dec 23
8-K
Departure of Directors or Certain Officers
12 Dec 23
8-K
NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America
11 Dec 23
8-K
NEXGEL Acquires Kenkoderm Psoriasis Skincare Line
5 Dec 23
8-K
NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
13 Nov 23
8-K
NEXGEL Secures Supply Agreement with AbbVie
30 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
21 Feb 24
S-3/A
Shelf registration (amended)
26 May 23
S-3
Shelf registration
13 Apr 22
424B4
Prospectus supplement with pricing info
27 Dec 21
S-1MEF
Registration of additional securities for an S-1
21 Dec 21
8-A12B
Registration of securities on exchange
15 Dec 21
S-1/A
IPO registration (amended)
10 Dec 21
S-1/A
IPO registration (amended)
6 Dec 21
S-1/A
IPO registration (amended)
2 Dec 21
S-1
IPO registration
9 Nov 21
Proxies
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Jul 22
DEF 14A
Definitive proxy
18 Jul 22
PRE 14A
Preliminary proxy
8 Jul 22
DEF 14C
Information statement
12 Jul 21
PRE 14C
Preliminary information
30 Jun 21
DEF 14C
Information statement
16 Mar 20
PRE 14C
Preliminary information
3 Mar 20
Other
EFFECT
Notice of effectiveness
8 Jun 23
CORRESP
Correspondence with SEC
7 Jun 23
CORRESP
Correspondence with SEC
7 Jun 23
UPLOAD
Letter from SEC
18 Apr 22
EFFECT
Notice of effectiveness
21 Dec 21
CORRESP
Correspondence with SEC
17 Dec 21
CORRESP
Correspondence with SEC
17 Dec 21
CERT
Certification of approval for exchange listing
16 Dec 21
CORRESP
Correspondence with SEC
16 Dec 21
CORRESP
Correspondence with SEC
14 Dec 21
Ownership
4
Scott Robert Henry
5 Mar 24
4
steven mark glassman
5 Mar 24
4
Adam E Drapczuk III
5 Mar 24
4
steven mark glassman
26 Dec 23
4
John Nachum Stein
28 Sep 23
4
Scott Robert Henry
14 Sep 23
4
Scott Robert Henry
23 Aug 23
4
Miranda Jayne Toledano
21 Aug 23
4
JEROME B ZELDIS
21 Aug 23
4
John Nachum Stein
21 Aug 23